Tiziana Life Sciences Ltd

TLSA

1.730USD

+0.070+4.22%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

233 / 507

Overall Ranking

412 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

8.000

Target Price

+379.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.

Undervalued

The company’s latest PE is -15.09, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 51.10M shares, increasing 15.98% quarter-over-quarter.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -15.09, which is -60.36% below the recent high of -5.98 and 43.29% above the recent low of -8.56.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 233/507

No Data

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Tiziana Life Sciences Ltd is 8.00, with a high of 8.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.97, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 2.02 and the support level at 1.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.97

Change

0

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-17

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cerrone (Gabriele M)

42.04M

+6.85%

Chernett (Jorey)

5.95M

--

Dauntless Investment Group, LLC

1.74M

--

HSBC Global Asset Management (UK) Limited

105.36K

--

Zhang Financial LLC

96.26K

+3.30%

Susquehanna International Group, LLP

57.33K

--

HRT Financial LP

70.37K

--

Kovitz Investment Group Partners, LLC

79.36K

--

Geode Capital Management, L.L.C.

77.89K

-68.30%



1

2



The company’s current risk assessment score is 3.22, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Tiziana Life Sciences Ltd

TLSA

4.04 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.85 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ACADIA Pharmaceuticals Inc

ACAD

7.65 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Zymeworks Inc

ZYME

7.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment